20th Annual Scientific Meeting Posters

Click to view poster or abstract. Posters are listed in order by first author.

Basket trial designs for CNS diseases: The benefits and the drawbacks (Abstract)

Adler

Identification and prospective replication of an EEG biomarker for predicting the antidepressant effect of ALTO-300 (Abstract)

Avissar

Consistency checks to improve measurement of agitation in a clinical trial setting (Abstract)

Belanger

Developing the first clinical outcome assessment for opioid craving as an FDA qualified drug development tool (Abstract)

Bergeria

Correspondence between recalled versus daily eDiary assessments of headache frequencies in episodic migraine (Abstract)

Besedina

Advancing Alzheimer’s disease research with patient-centric digital endpoints of function (Abstract)

Blankenship

Validation of the web based version of the CDR System (Abstract)

Brooker

Measuring remission and response using CDRS-R and MADRS in adolescents with MDD and imminent suicide risk (Abstract)

Cai Shi

Speech latency analysis for clinical trial enrichment: Towards industrial scalability (Abstract)

Cohen

Efficacy of recruitment techniques for a decentralized trial of a digital therapeutic for migraine (Abstract)

Colbert

Analysis of correlation of the Clinical and Patient Global Impression of Improvement Scales in acute schizophrenia trials (Abstract)

Companioni

Improving administration and scoring in CAPS-5 (Abstract)

Conrad

Optimizing diagnostic efficiency: Trade-off analysis of RAVLT trials (Abstract)

Dorr

Impact of rater change on data variability in MADRS total score using site vs independent raters (Abstract)

Echevarria

Evaluating impact of digital health technology tool use on efficacy and adherence in schizophrenia trials (Abstract)

Fan

Evaluating drug efficacy: Leveraging machine learning insights from placebo response modeling (Abstract)

Geraci

Identifying efficacy variables for escitalopram in mild MDD: Implications for TRD trials (Abstract)

Geraci

Using active and passive digital phenotyping to increase signals in early stage drug development trials (Abstract)

Harvey

Further evaluation of pro-cognitive effect of KarXT in acutely symptomatic schizophrenia (Abstract)

Horan

Test-retest reliability and practice effects on NIH Toolbox Cognition Battery in Duchenne muscular dystrophy (Abstract)

Kaat

Emotional valence of picture stimuli modulates audio and video digital measurements in schizophrenia (Abstract)

Kark

Within-subject changes in MADRS correlated with changes in audio-video digital traits (Abstract)

Kark

Remote verbal learning over repeated exposures for six months (Abstract)

Kaula

Development of the Episodic Agitation Scale (Abstract)

Kay

Placebo response prediction for optimizing treatment effect estimation in MDD (Abstract)

Kogan

Relationship between sample size and responsiveness of speech-based digital biomarkers in ALS (Abstract)

Kothare

Sources of noise in PANSS ratings (Abstract)

Kott

Calibrating the optimized PANSS10 short form in three independent clinical trials (Abstract)

Langfus

Feasibility of a fully remote Phase II decentralized clinical trial in MDD: Lessons learned (Abstract)

Le Nguyen

An EEG-based ML biomarker to identify responsive vs non-responsive subjects in an MDD trial (Abstract)

Li

Automatic detection of cheating on remote word list learning tests using speech analysis (Abstract)

Mallick

Deriving cross-cognitive task outcome measures using dimensionality reduction techniques (Abstract)

McCoy

Charting schizophrenia: Investigating symptom landscapes recruited pre/post Covid-19 (Abstract)

Micaletto

An empirical view of our US primary endpoint evaluators’ work stress and task burnout (Abstract)

Montero

Towards fully automated rating scale review: speech feature signature for CDR interview variances (Abstract)

Newsome

Serial reschedulers: Relationship between repeated reschedules attendance and screening for MDD trials (Abstract)

Nicholas

Formation of a digital working alliance with a digital therapeutic to treat negative symptoms of schizophrenia (Abstract)

Pratap

Understanding the challenges of masking in psychedelic clinical trials: A comprehensive review (Abstract)

Price

Precision matters: Analysis of how various scores behave measuring change over time (Abstract)

Psimas

Quantitative standardized brain network activity measures to inform CNS treatment development (Abstract)

Setton

Different last 4 of ID provided – A red flag for the professional subject? (Abstract)

Shiovitz

Estimating heterogeneity of treatment effects in clinical trials (Abstract)

Siegel

Towards multimodal dysarthria assessment that incorporates clinical judgement (Abstract)

Simmatis

Are trial endpoints actually on point? Longitudinal measurement invariance in depression trials using MADRS (Abstract)

Sirbu

Clinical Outcome Assessments in clinical trials: When is the gold standard just the old standard (Abstract)

Skirrow

A pilot trial of symptom-triggered alcohol withdrawal management delivered over telemedicine (Abstract)

Sloan

Use of a novel pharmacogenomic biomarker to enrich responders for liafensine in TRD (Abstract)

Spear

Word of the day: Patient perspectives in a Phase 4 open-label study of adjunctive brexpiprazole in MDD (Abstract)

Therrien

Measuring clinically relevant change in apathy symptoms in ADMET & ADMET2 (Abstract)

Tumati

Investigating cognitive practice effects in schizophrenia using repeated assessment at short retest intervals (Abstract)

Wacker